PSMB5 and plasma cell myeloma: Bortezomib, a peptide boronic acid congener, directly inhibits the chymotrypsin‐like activity of the proteasome PSMB5 subunit and is used for the treatment of multiple myeloma; it is also undergoing clinical trials for the treatment of several epithelial cancers (Ria et al., 2014).